Pharmacists revise position on formularies
The Academy of Managed Care Pharmacy, Alexandria, VA, released a revised position statement supporting the appropriate design and use of drug formularies.
The Academy of Managed Care Pharmacy, Alexandria, VA, released a revised position statement supporting the appropriate design and use of drug formularies.
The academy's board of directors adopted the revised position statement in an effort to better inform the public, policy-makers and other health care professionals about the role formularies play in fostering the appropriate and effective use of prescription medications.
"A formulary enhances the quality of care by encouraging the use of those prescription medications that are demonstrated to be safe, effective and produce superior patient outcomes," according to the position statement.
The academy said a formulary works best when it supports and operates in conjunction with other tools that promote quality and optimal results, such as drug utilization review and medical treatment guidelines and prescribing protocols.
"Drug costs are not the overriding factor in determining which drugs to include on the formulary," according to the academy. "Decisions are also based in part on results of clinical trials, scientific studies, evaluation of the drug's role in disease treatment guidelines, comparisons with other like products and data that reflect the drug's actual or projected use in specific patient populations." PR
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
